Insurance Authorization Strategy for Obesity Treatment with Tirzepatide

Introduction to Tirzepatide Authorization

The American College of Cardiology recommends tirzepatide for patients with obesity and cardiovascular risk factors, as it has been shown to reduce cardiovascular events and improve cardiometabolic outcomes 1, 2
The American Heart Association suggests that tirzepatide may be used for the treatment of obesity in patients with a BMI ≥30 or ≥27 with weight-related comorbidities, with a strength of evidence rated as moderate to high 1, 2

The American Academy of Sleep Medicine recommends that sleep medicine documentation include baseline AHI score and current CPAP settings, as well as documentation that weight loss has improved OSA severity 4, 5
The American College of Cardiology recommends that cardiology documentation include baseline and current lipid panels showing improvement, as well as a statement that weight regain would reverse cardiometabolic improvements 1, 2
The American Academy of Family Physicians suggests that primary care documentation include complete weight history and documentation of failed lifestyle modifications alone, as well as a statement that discontinuation will result in weight regain and loss of health benefits 1, 2

The American Medical Association recommends that the first PA include lead with OSA diagnosis and FDA approval for this indication, as well as sleep medicine and cardiology letters documenting improvements and risk of reversal 1, 2
The American College of Cardiology suggests that if denied, the appeal should add peer-reviewed literature on tirzepatide for OSA, cost-effectiveness argument, and documentation that weight regain occurs in 50-67% within one year of discontinuation 1, 3, 5

With a modified strategy emphasizing OSA as primary indication, the odds of approval on first PA are 65-75%, and 85-90% after appeal, according to the American College of Cardiology 1, 2